WINSTON-SALEM, N.C., Sept. 24 (UPI) -- Inhaled anti-cholinergic agents by patients with chronic obstructive pulmonary disease is linked to increased risk of heart attack, U.S. researchers said.
Inhaled anti-cholinergic agents -- including ipratropium bromide or tiotropium bromide -- are widely used in patients with COPD. Inhaled tiotropium is the most widely prescribed medication for COPD, with more than 8 million patients worldwide having used it since its approval in 2002, said Dr. Sonal Singh of Wake Forest University School of Medicine in Winston-Salem, N.C.
Singh and colleagues conducted a meta-analysis to determine cardiovascular risks of heart attacks, stroke and cardiovascular death associated with the long-term use of inhaled anti-cholinergics. After identifying and screening of 103 articles, 17 randomized trials involving 14,783 patients were analyzed.
The analysis, published in the Journal of the American Medical Association, indicated that inhaled anti-cholinergics significantly increased the risk, by 58 percent, of cardiovascular death, heart attack, or stroke -- 1.8 percent versus 1.2 percent for controls, the researchers said.
